Business UpdateNov 5, 2026, 04:07 PM
PMGC Holdings Signs Marketing Agreements; Subsidiary Announces Preclinical Study Update
AI Summary
PMGC Holdings Inc. has entered into two new agreements to enhance its investor relations and marketing efforts. The company signed a Consulting Agreement with IR Agency LLC for $300,000 and a Digital Marketing Services Agreement with Senergy Communications Capital Inc. for C$185,000. Additionally, its subsidiary NorthStrive Biosciences announced preliminary results from a preclinical study of its EL-32 candidate in combination with Semaglutide, indicating potential lean-mass preservation findings and informing the strategy for a planned follow-on study in Q1 2027.
Key Highlights
- PMGC Holdings Inc. entered into a Consulting Agreement with IR Agency LLC for marketing and advertising services.
- The agreement with IR Agency LLC is for a term of up to three months, with a total compensation of $300,000.
- PMGC Holdings Inc. also entered into a Digital Marketing Services Agreement with Senergy Communications Capital Inc.
- The Senergy Communications Capital Inc. agreement is for approximately one month, with a total compensation of C$185,000.
- NorthStrive Biosciences announced preliminary results from its EL-32 Preclinical Combination Study with Semaglutide.
- The study showed preliminary lean-mass findings at the highest EL-32 dose and informed future preclinical development strategy.
- NorthStrive plans a follow-on preclinical study for EL-32 in combination with a lower dose of semaglutide in Q1 2027.
Price Impact
More from ELAB